Latest News and Press Releases

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Updates on INZ-701

JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...

Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.

Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.

Inozyme announced that it will host a conference call and webcast on Monday, Apr. 8, 2024 at 8:00 a.m. ET.

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...

– U.S. Food and Drug Administration cleared Investigational New Drug Application – – United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application – –...